Fatty Acid Synthase (FASN) is a multifunctional homodimeric enzyme protein, and it is the major enzyme required for the anabolic conversion of dietary carbohydrates to fatty acids.In the presence of NADPH, fatty acid synthase catalyzes the conversion of acetyl-CoA and malonyl-CoA into long-chain saturated fatty acids.
Palmitic acid is produced by the sizable homodimeric multifunctional enzyme known as human fatty acid synthase. Fatty acid synthase's distinctive carboxyl terminal thioesterase domain hydrolyzes the lengthening fatty acid chain and is essential for controlling the amount of fatty acid released. Additionally, the thioesterase is a candidate target for therapeutic intervention due to the up-regulation of human fatty acid synthase in a variety of cancers.
|Denifanstat (TVB-2640; FASN-IN-2; ASC-40; TVB2640) is a novel, potent and orally bioactive fatty acid synthase (FASN) inhibitor with potential anticancer activity and may also be used for the Treatment of Nonalcoholic Steatohepatitis.
|Fatostatin A is a novel, potent and cell permeable inhibitor of SREBP (Sterol regulatory element-binding protein) activation with anticancer activity.
|Fatostatin HBr, the hydrobromide salt of fatostatin A, is a novel, potent and cell permeable inhibitor of SREBP (Sterol regulatory element-binding protein) activation by directly binding SCAP and blocking its ER-to-Golgi transport with IC50 of 2.5 and 10 μM in mammalian cells.
|Orlistat (also known as tetrahydrolipstatin, or Ro 18-0647, Lipase Inhibitor, THL ) is a potent and general lipase inhibitor with IC50 of 122 ng/ml for PL from human duodenal juice.
|TVB-3166 is a novel, potent, orally bioavailable, reversible and selective inhibitor of fatty acid synthase (FASN) inhibitor (IC50s of 42 nM and 81 nM in biochemical and cellular assay, respectively.
|TVB-3664 (TVB3664) is a novel and potent fatty acid synthase (FASN)inhibitor that isorally bioavailable, reversible, and selective.